Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06403332
Status:
RECRUITING
Last Update Posted:
2024-05-07
First Post:
2024-04-24
Brief Title:
Study of the Drivers of Late Diagnosis of Alcohol Related Diseases Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease Implementation and Evaluation of Itnerventions to Reduce Its Burden
Sponsor:
Hospital Universitari Vall dHebron Research Institute
Organization:
Hospital Universitari Vall dHebron Research Institute
Study Overview
Official Title:
Study of the Drivers of Late Diagnosis of Alcohol Related Diseases Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease Implementation and Evaluation of Itnerventions to Reduce Its Burden
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
StopALD
Brief Summary:
Excessive alcohol use is a leading risk factor for preventable disability and death Alcohol-related liver disease ALD is one of the better-known detrimental consequences of alcohol abuse and is the main cause of disability-adjusted life years DALYs in European adults ALD is the main cause of cirrhosis globally and is responsible for 60 of cirrhosis in Europe and North America
Importantly another etiology of liver disease is on the rise due to the epidemics of obesity and diabetes mellitus in Western countries ie metabolic dysfunction associated fatty liver disease MAFLD ALD and MAFLD are largely shaped by social determinants of health SDH and lead to mounting health inequalities Moreover ALD is subject to strong stigmatization particularly amongst women which often leads to lack of inquiry by health professionals Alone or in combination MAFLD-OH both diseases represent a challenge for epidemiologists clinicians and policy makers in charge of health systems organization One of the hurdles to reduce the burden of ALD is the lack of early detection of asymptomatic liver disease among patients with alcohol use disorder AUD and heavy drinkers The only measure that has been proven effective in any phase of the disease is to either stop compensate or reverse the liver disease progression is alcohol abstinence We hypothesize that establishing effective screening programs to identify patients with ALD and related disorders coupled with effective treatment will lead to more positive outcomes in prognosis The central aim of the StopALD Project is to identify patients with advanced ALD during the asymptomatic phases of the disease as well as identifying the factors related with the lack of early detection to better implement interventions so to tackle both the lack of early detection of ALD and heavy drinking patterns among young people before ALD occurs
Importantly another etiology of liver disease is on the rise due to the epidemics of obesity and diabetes mellitus in Western countries ie metabolic dysfunction associated fatty liver disease MAFLD ALD and MAFLD are largely shaped by social determinants of health SDH and lead to mounting health inequalities Moreover ALD is subject to strong stigmatization particularly amongst women which often leads to lack of inquiry by health professionals Alone or in combination MAFLD-OH both diseases represent a challenge for epidemiologists clinicians and policy makers in charge of health systems organization One of the hurdles to reduce the burden of ALD is the lack of early detection of asymptomatic liver disease among patients with alcohol use disorder AUD and heavy drinkers The only measure that has been proven effective in any phase of the disease is to either stop compensate or reverse the liver disease progression is alcohol abstinence We hypothesize that establishing effective screening programs to identify patients with ALD and related disorders coupled with effective treatment will lead to more positive outcomes in prognosis The central aim of the StopALD Project is to identify patients with advanced ALD during the asymptomatic phases of the disease as well as identifying the factors related with the lack of early detection to better implement interventions so to tackle both the lack of early detection of ALD and heavy drinking patterns among young people before ALD occurs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None